This post hoc analysis of a randomized clinical trial examines factors associated with short-term relapse in patients with pemphigus treated with rituximab.
This cohort study evaluates the association between use of rituximab and remission in patients with pemphigus.
This cross-sectional analysis using Explorys data examines the prevalence of pemphigus in US adults across age, sex, and race groups.
This cross-sectional study estimates the association between pemphigus and a wide range of nonhematologic malignancies by examining a large cohort of patients with pemphigus.
This population-based cross-sectional study estimates the association between pemphigus and 4 neurologic conditions using one of the largest cohorts of patients with pemphigus.
This case-series study of 11 patients with severe, difficult-to-treat pemphigus examines whether rituximab alone can be used long-term as maintenance therapy for prevention of relapse.
This study examines the incidence of and risk factors for hospitalization for patients with pemphigus and cost of care.
In this case series evaluating intralesional rituximab injections for pemphigus vulgaris in 3 patients, the treatment had no adverse effects, reduced the amount of drug administered, and was less expensive than intravenous administration.
This case describes opportunistic infection with Trichosporon inkin refractory to conventional antifungal treatment.
This case series suggests the use of a combination of rituximab and topical corticosteroids in the treatment of pemphigus vulgaris.
Ellebrecht et al describe the use of veltuzumab, a second-generation humanized anti-CD20 antibody, in a patient with pemphigus vulgaris.
Heelan et al assess the clinical response of patients with pemphigus to rituximab using a modified fixed-dose rheumatoid arthritis protocol.
Rahbar and coauthors evaluate clinical pemphigus disease activity measurements.
You currently have no searches saved.
Create a personal account or sign in to: